What is CGEM (CGEM) stock price today?

CGEM (CGEM) is currently trading at $22.33, up 2.48% today.

What is CGEM P/E ratio?

CGEM's P/E ratio is -3.76. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CGEM return on equity (ROE)?

CGEM's return on equity (ROE) is -53.79%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CGEM's market cap?

CGEM has a market capitalization of $1.37B.

NASDAQ · Medical - Pharmaceuticals

CGEM (CGEM) Stock

$22.33 +2.48% NASDAQ: CGEM Healthcare

Valuation

Metric	Value
Price	$22.33
Market Cap	$1.37B
P/E Ratio	-3.76
P/B Ratio	2.10
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$23.08
52-Week Low	$5.68
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-53.79%
ROA	-49.11%
ROCE	-59.31%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	10.18

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$19.0M	$0	$0	$0	$0
Operating Profit	$-68.0M	$145.0M	$-191.0M	$-197.0M	$-242.0M
Net Profit	$-66.0M	$111.0M	$-153.0M	$-167.0M	$-220.0M
EPS	$-1.48	$2.38	$-3.69	$-3.11	$-3.72
Op Margin	-358.7%	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$437.0M	$561.0M	$484.0M	$622.0M	$448.0M
Total Liabilities	$12.0M	$26.0M	$30.0M	$31.0M	$40.0M
Cash	$60.0M	$156.0M	$98.0M	$83.0M	$88.0M
Borrowings	$0	$5.0M	$4.0M	$2.0M	$3.0M

Latest News

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes Simply Wall St. · Jun 23, 2026 Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing Exec Edge · Jun 22, 2026 Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps MT Newswires · Jun 10, 2026 Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases GlobeNewswire · Jun 10, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-43.0M	$-127.0M	$-134.0M	$-145.0M	$-176.0M
Investing Cash Flow	$-334.0M	$248.0M	$36.0M	$-136.0M	$180.0M
Financing Cash Flow	$2.0M	$-32.0M	$1.0M	$4.0M	$0
Net Cash Flow	$-108.0M	$96.0M	$-58.0M	$-15.0M	$5.0M
Free Cash Flow	$-44.0M	$-128.0M	$-134.0M	$-145.0M	$-176.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-20.72%
Quick Ratio	10.28
Interest Coverage	—
Return 1Y	107.44%
Return 3Y	67.44%
Return 5Y	-33.52%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADCT	$1.32	+6.88%	-1.99	$167.89M	0.00%
BCYCBicycle Therapeutics plc	$4.22	+0.24%	-1.34	$292.84M	0.00%
CBLL	$24.81	+0.94%	-11.62	$941.36M	0.00%
EHABEnhabit Inc	$13.80	+0.07%	-153.33	$706.91M	0.00%
LAB	$0.67	+3.51%	-5.30	$263.57M	0.00%

About CGEM

CGEM is led by CEO Nadim Ahmed, employs 111 people, headquartered in US, publicly traded since 2021.

CGEM stock trades at $22.33 with a market capitalization of $1.37B. The stock is valued at a price-to-earnings (P/E) ratio of -3.76, price-to-book of 2.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.68 and $23.08, and currently trades 3.2% below its 52-week high.

On profitability, CGEM generates a return on equity (ROE) of -53.79%, return on capital employed of -59.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides